The antibody technology from Andersen’s team will be used in the development of Mage's lead tailored monoclonal antibody for clinical use. This is a result of a long-term collaboration between Tillots Pharma and Jan Terje Andersen’s team where Tillott has now re-licensed the technology to the new company Mage Bio. The in-licensing agreement is negotiated through Inven2.
Read more about the story on Inven2’s webpage and at MEDWATCH.